CapsoVision (NASDAQ:CV) Issues Earnings Results

CapsoVision (NASDAQ:CV) issued its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, FiscalAI reports. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 165.96%. The firm had revenue of $3.64 million for the quarter.

Here are the key takeaways from CapsoVision’s conference call:

• Commercial momentum continued: Q2 revenue rose 10% year over year to $3.6 million, while CapsoCam Plus capsule shipments increased 13% and total patients imaged reached more than 176,000. Management also cited customer renewals and growing adoption among large hospital systems and GI networks.
• AI Highlights launched internationally and is expected to support physician efficiency and broader platform adoption. The company anticipates FDA clearance by the end of Q3 and a U.S. launch shortly thereafter, although management cautioned that clearance is not guaranteed.
• Gross margin declined to 51% from 55% a year ago because of competitive pricing pressure and higher inbound customs and tariff costs. Operating expenses also increased substantially to $9.5 million, driven by clinical and product development investments, public-company costs, and stock-based compensation.
• The CapsoCam Colon FDA submission was pushed back one quarter to Q4 2026 because the company needs additional positive subjects with significant polyps, increasing development and timing risk despite management’s confidence in the second-generation platform.
• Management expects second-half 2026 revenue to exceed first-half revenue, with Q4 typically the strongest quarter due to seasonality. The company ended Q2 with $9.1 million in cash and has access to a $100 million at-the-market equity program, providing additional funding flexibility.

CapsoVision Price Performance

CV stock traded down $0.33 during mid-day trading on Friday, reaching $6.46. The company had a trading volume of 151,842 shares, compared to its average volume of 96,524. The company has a market capitalization of $322.77 million and a PE ratio of -2.76. The firm has a 50 day moving average of $6.77 and a 200 day moving average of $6.33. CapsoVision has a 12 month low of $3.43 and a 12 month high of $15.37.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CV shares. Weiss Ratings restated a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Insider Buying and Selling at CapsoVision

In related news, major shareholder Eliyahou Et Al Harari purchased 61,068 shares of the firm’s stock in a transaction dated Friday, July 17th. The stock was purchased at an average price of $6.73 per share, with a total value of $410,987.64. Following the completion of the purchase, the insider owned 3,343,119 shares of the company’s stock, valued at approximately $22,499,190.87. The trade was a 1.86% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 156,218 shares of company stock worth $1,007,902 over the last ninety days. Insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of CapsoVision in the 2nd quarter worth $14,372,000. Bank of New York Mellon Corp bought a new position in shares of CapsoVision during the 2nd quarter worth $569,000. State Street Corp increased its stake in shares of CapsoVision by 340.7% during the fourth quarter. State Street Corp now owns 85,929 shares of the company’s stock valued at $919,000 after buying an additional 66,429 shares during the period. Geode Capital Management LLC increased its stake in shares of CapsoVision by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock valued at $1,649,000 after buying an additional 39,231 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of CapsoVision in the second quarter valued at about $263,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.